Compare KraneShares Hang Seng TECH Index ETF (KTEC) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KraneShares Hang Seng TECH Index ETF vs Natera Inc. Common Stock — how do they compare? KraneShares Hang Seng TECH Index ETF trades at $11.52 (market cap $46.22M), while Natera Inc. Common Stock trades at $394 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 1233.9× KraneShares Hang Seng TECH Index ETF's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, KraneShares Hang Seng TECH Index ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold KraneShares Hang Seng TECH Index ETF for 44 Days and Natera Inc. Common Stock for 0 Days on average.
| KTEC | NTRA | |
|---|---|---|
Market Cap | $46.22M | $57.03B |
Volume | 22,698 | 1,131,157 |
Sector | Sector/Thematic | Health |
52-Week High | $18.36 | $425.64 |
52-Week Low | $11.41 | $179.42 |
Typical Hold Time | 44 Days | 0 Days |
Enterprise Value | — | $56.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KTEC trades at $11.61 with no recent price movement. The stock shows bearish technical signals with 15 sell indicators versus 2 buy signals. Fundamentally, the company reported $120.04M revenue in 2016 with a net loss of $697K, though cash flow improved to positive $2.77M. Recent news highlights China's AI competition potentially benefiting tech ETFs like KTEC.
KTEC faces mixed prospects with improving cash flow but inconsistent profitability. The bearish technical outlook and volatile earnings history suggest caution, though exposure to AI sector growth through ETF positioning offers potential upside. Key risks include competitive pressures and execution challenges in maintaining positive momentum.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About KraneShares Hang Seng TECH Index ETF
KTEC tracks the Hang Seng TECH Index, providing targeted exposure to the 30 largest technology companies listed on the Hong Kong Stock Exchange. It focuses on innovative, internet-based businesses across sectors like e-commerce, fintech, cloud computing, and digital technology.
Read more on KTEC →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
